Richard Saynor was appointed CEO at Sandoz in 2019, with a mission to turn the Novartis generics and biosimilars division into the world’s leading and most valued generics company. Today, these efforts are well on track. Sandoz reaches 500 million patients a year with its broad portfolio of affordable medicines. Saynor was named Leader of the Year in the 2020 Global Generics & Biosimilars Awards for his efforts. Saynor has a wealth of experience in the pharmaceutical industry. He previously held regional leadership roles at Sandoz between 2005 and 2010.